Mural Oncology plc MURA 深 滬
已收盤 12-05 16:00:00 美东时间
2.04
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 2.04
- 總市值 3534.18万
- 52周最高 4.74
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.95
- 委 比 0.00%
- 總股本 1732.44万
- 歷史最高 17.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.95
- 每 手 1
- 風險率 0.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mural Oncology Announces Sanction of the Scheme by the High Court
Mural Oncology plc has announced that the High Court of Ireland has approved a scheme of arrangement under the Companies Act 2014. This scheme allows XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, to acquire 100% of Mural's shares. The acquisition is expected to become effective on December 5, 2025, after the court order is delivered to the Irish Registrar of Companies. Consequently, trading of Mural shares on Nasdaq will cease on Decembe...
12-03 21:30
Mural Oncology Shareholders To Receive $2.035 Per Share As XOMA Royalty Acquisition; Set To Close In Early December 2025
Mural Oncology plc (NASDAQ:MURA) ("Mural") announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"), XRA 5 Corp. ("Sub") and Mural
11-26 22:03
Mural Oncology Shareholders Approve Takeover Of XOMA Royalty's XRA 5 Unit
Mural Oncology plc (NASDAQ:MURA) ("Mural") today announced that its shareholders have voted to approve the previously announced proposed acquisition of Mural by XRA 5 Corp. ("Sub"), a wholly owned subsidiary of XOMA
10-25 04:27
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
WALTHAM, Mass. and DUBLIN, Ireland – Mural Oncology plc shareholders approved the acquisition by XRA 5 Corp., with over 99% of votes cast in favor at both the Scheme Meeting and Extraordinary General Meeting. Under the transaction, each Mural shareholder will receive a base cash price of $2.035 per share, with an additional potential $0.205 per share based on Closing Net Cash. The acquisition, valued at approximately $36.2 million, is expected to...
10-24 20:25
SHIMAMURA Co. Reports Steady Growth in Latest Earnings
SHIMAMURA Co ( ($SHAOF) ) has released its Q2 earnings. Here is a breakdown of ...
10-22 12:05
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
Mural Oncology announced the publication of its definitive proxy statement for shareholders regarding the acquisition by XOMA Royalty, which will be voted on at the Scheme Meeting and Extraordinary General Meeting on October 24, 2025, in Dublin. The proxy statement includes details of the acquisition terms, voting instructions, and the treatment of equity awards under the Irish Takeover Rules. Shareholders are urged to review the proxy statement,...
09-23 23:52
Mural Oncology shares are trading higher after the company announced it will be acquired by a Xoma Royalty subsidiary for between $2.035 and $2.24 cash per share.
Mural Oncology shares are trading higher after the company announced it will be...
08-21 01:38
Mural Oncology Plc Announces Acquisition Agreement
Mural Oncology Plc ( ($MURA) ) just unveiled an announcement. On August 20, 202...
08-20 21:18
Mural Oncology Q2 EPS $(2.78) Misses $(1.51) Estimate
Mural Oncology (NASDAQ:MURA) reported quarterly losses of $(2.78) per share which missed the analyst consensus estimate of $(1.51) by 84.11 percent. This is a 49.46 percent decrease over losses of $(1.86) per share from
08-04 20:19
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
Mural Oncology plc announced its second-quarter 2025 financial results and business update. The company discontinued clinical development of its lead product candidate, nemvaleukin alfa, and is exploring strategic alternatives to maximize shareholder value. Cash and cash equivalents were $77.1 million as of June 30, 2025, with an estimated $43 million to $48 million by December 31, 2025, if no strategic transaction is completed. The company incur...
08-04 12:00
